Search Results - "Burris H"

Studies of turbulent oxyacetylene flames used for diamond growth.

Authors: Marks, C. M. Burris, H. R. Grun, J.

Source: Journal of Applied Physics; January 15 1993, Vol. 73, p755-759, 5p

Short-pulse range-gated optical imaging in turbid water.

Authors: McLean, E. A. Burris, H. R. Strand, M. P.

Source: Applied Optics; July 20 1995, Vol. 34, p4343-4351, 9p

Approach for quiet neighborhood planning.

Authors: Burris, H. T.

Source: Sound; Its Uses & Control; September 1962, Vol. 1, p7-12, 6p

Prenatal vitamin use and vitamin D status during pregnancy, differences by race and overweight status.

Authors: Burris, H H Thomas, A Zera, C A et al.

Source: Journal of Perinatology. Apr2015, Vol. 35 Issue 4, p241-245. 5p.

Intermittent dosing of axitinib combined with chemotherapy is supported by ¹⁸FLT-PET in gastrointestinal tumours.

Authors: Hoh, C K Burris, H A Bendell, J C et al.

Source: British Journal of Cancer. 2/18/2014, Vol. 110 Issue 4, p875-881. 7p. 1 Color Photograph, 2 Charts, 3 Graphs.

Getting research into policy - Herpes simplex virus type-2 (HSV-2) treatment and HIV infection: international guidelines formulation and the case of Ghana.

Authors: Burris, H. Parkhurst, J. Adu-Sarkodie, Y. et al.

Source: Health Research Policy & Systems. Jan2011 Supplement 1, Vol. 9, p1-10. 10p.

Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.

Authors: Burris, H. A.¹ howard.burris@scresearch.net

Source: Oncogene. 8/2/2009 Supplement, Vol. 28, pS4-S13. 10p. 2 Diagrams, 1 Chart.

Authors: Holton, Thomas L. Burris, H. Barry Chapin, Donald H. et al.

Source: Journal of Accountancy. Feb1972, Vol. 133 Issue 2, p64-70. 7p.

Subject Terms: *Auditing, *Auditors' reports, *Auditing policies, *Auditing procedures, *Accountant independence, *Accounting standards, *Conferences & conventions

Company/Entity: American Institute of Certified Public Accountants

Evaluating statin-induced protection against liver cancer in patients with chronic liver disease: insights from a large regional health data repository.

Authors: Yu, Z. Burris, H. Pereira, N. et al.

Source: HPB (1365-182X). 2024 Supplement 1, Vol. 26, pS108-S108. 1p.

Free-space optical communications research and demonstrations at the U.S. Naval Research Laboratory.

Authors: RABINOVICH, W. S. MOORE, C. I. MAHON, R. et al.

Source: Applied Optics (1559-128X); 11/1/2015, Vol. 54 Issue 31, pF189-F200, 12p

Free-space optical communications link at 1550 nm using multiple-quantum-well modulating retroreflectors in a marine environment.

Authors: Rabinovich, W. S. Mahon, R. Burris, H. R.

Source: Optical Engineering; May 2005, Vol. 44 Issue 5, p056001-056001, 1p

Disparities in antidepressant use in pregnancy.

Authors: Yamamoto, A McCormick, M C Burris, H H

Source: Journal of Perinatology. Apr2015, Vol. 35 Issue 4, p246-251. 6p.

605 A Phase 1, Open-label, Dose-escalation Study of Oral Administration of the Investigational Agent MLN0128 in Combination with Paclitaxel (P) in Patients (pts) with Advanced Solid Malignancies

Authors: Burris, H. Hart, L. Kurkjian, C. et al.

Source: European Journal of Cancer. Nov2012 Supplement, Vol. 48, p186-186. 1p.

193 Phase I Safety Experience with the Oral Pan-class I PI3K Inhibitor BKM120 in Patients with Metastatic Breast Cancer (mBC)

Authors: Saura, C. Burris, H. Arteaga, C.L. et al.

Source: European Journal of Cancer. Mar2012 Supplement, Vol. 48 Issue s2, pS96-S96. 1p.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Authors: Hortobagyi, G N Stemmer, S M Burris, H A et al.

Source: Annals of Oncology. Jul2018, Vol. 29 Issue 7, p1541-1547. 7p. 1 Diagram, 2 Charts, 2 Graphs.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Authors: Hortobagyi, G. N. Stemmer, S. M. Burris, H. A. et al.

Source: New England Journal of Medicine. 11/3/2016, Vol. 375 Issue 18, p1738-1748. 11p.

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.

Authors: Younes, A. Vose, J. M. Zelenetz, A. D. et al.

Source: British Journal of Cancer. 12/7/2010, Vol. 103 Issue 12, p1783-1787. 5p. 2 Charts, 2 Graphs.

760 Severe maternal morbidity and preterm birth rates in pregnant women with cystic fibrosis.

Authors: Barnidge, M. Dysart, K. Clausen, E. et al.

Source: Journal of Cystic Fibrosis. 2025 Supplement 2, Vol. 24, pS460-S460. 1p.

Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network.

Authors: Hainsworth, John D. Burris III, Howard A. Calvert, Sharon W. et al.

Source: Cancer Investigation. Apr2001, Vol. 19 Issue 4, p335-339. 5p. 2 Charts.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Authors: Hortobagyi, G N Stemmer, S M Burris, H A et al.

Source: Annals of Oncology. Nov2019, Vol. 30 Issue 11, p1842-1842. 1p.